Levetiracetam Tablet, Film Coated
Product Images NDC 43063-617

12 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43063-617). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (24fe2e98 0b9f 4eea A745 E26002329cec 01)

Figure 1 (24fe2e98 0b9f 4eea A745 E26002329cec 01)
A mathematical formula for calculating total daily dose (mL/day) of a medication based on daily dose (mg/kg/day), patient weight (kg), and concentration (100 mg/mL). The formula divides the product of daily dose and patient weight by 100 mg/mL.*
FDA Label Image

Figure 2 (24fe2e98 0b9f 4eea A745 E26002329cec 02)

Figure 2 (24fe2e98 0b9f 4eea A745 E26002329cec 02)
This image shows a text excerpt explaining the formula for calculating creatinine clearance (CLcr), including adjustments for body surface area and a factor for female patients. It includes variables such as age, weight, serum creatinine, and body surface area.*
FDA Label Image

Structure (24fe2e98 0b9f 4eea A745 E26002329cec 03)

Structure (24fe2e98 0b9f 4eea A745 E26002329cec 03)
Chemical structure of the active ingredient Levetiracetam, showing its molecular components including a pyrrolidone ring and side chains.*
FDA Label Image

Figure 4 (24fe2e98 0b9f 4eea A745 E26002329cec 04)

Figure 4 (24fe2e98 0b9f 4eea A745 E26002329cec 04)
Bar chart depicting the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis shows percent of patients from 0% to 45%. Placebo group has 7.4%, Levetiracetam 1000 mg/day has 37.1%, and Levetiracetam 3000 mg/day has 39.6%. Sample sizes (N) are indicated under each group label on the x-axis.*
FDA Label Image

Figure 5 (24fe2e98 0b9f 4eea A745 E26002329cec 05)

Figure 5 (24fe2e98 0b9f 4eea A745 E26002329cec 05)
A bar chart comparing the percentage of patients across three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, with values ranging from 0% to 45%. Percentages are displayed above each bar: 6.3% for placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day.*
FDA Label Image

Figure 6 (24fe2e98 0b9f 4eea A745 E26002329cec 06)

Figure 6 (24fe2e98 0b9f 4eea A745 E26002329cec 06)
A bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Levetiracetam 3000 mg/day (N=180) with 39.4%, indicating a higher percentage of patients in the Levetiracetam group. The vertical axis is labeled as % of Patients.*
FDA Label Image

Figure 7 (24fe2e98 0b9f 4eea A745 E26002329cec 07)

Figure 7 (24fe2e98 0b9f 4eea A745 E26002329cec 07)
A bar chart comparing the percentage of patients responding to placebo versus Levetiracetam. The chart shows 19.6% for placebo (N=97) and 44.6% for Levetiracetam (N=101), with the y-axis labeled '% of Patients.'*
FDA Label Image

Figure 8 (24fe2e98 0b9f 4eea A745 E26002329cec 08)

Figure 8 (24fe2e98 0b9f 4eea A745 E26002329cec 08)
A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis shows percentage of patients from 0% to 45%. The placebo group (N=51) shows 19.6%, while the Levetiracetam group (N=58) shows 43.1%. Asterisk symbol present above the Levetiracetam bar.*
FDA Label Image

Figure 9 (24fe2e98 0b9f 4eea A745 E26002329cec 09)

Figure 9 (24fe2e98 0b9f 4eea A745 E26002329cec 09)
A bar graph comparing the percentage of patients responding to Placebo and Levetiracetam treatment groups. The y-axis shows percentage of patients from 0% to 100%. The Placebo group (N=84) shows 45.2%, while the Levetiracetam group (N=79) shows 72.2%, indicating a higher response rate with Levetiracetam.*
FDA Label Image

Image (D1c36ef8 B1ae 459b B232 Dec8100baf09 615 1)

Image (D1c36ef8 B1ae 459b B232 Dec8100baf09 615 1)
Levetiracetam 500 mg film-coated oral tablets. The image shows one white round tablet with a break line, displayed over a black and white flower-like pattern on the background. The packaging or labeler information is not visible in the image.*
FDA Label Image

Image (D1c36ef8 B1ae 459b B232 Dec8100baf09 638 1)

Image (D1c36ef8 B1ae 459b B232 Dec8100baf09 638 1)
Levetiracetam 500 mg film-coated tablets packaging with distinctive black geometric floral pattern on a white background. The product is labeled by PD-Rx Pharmaceuticals, Inc. and intended for oral administration.*
FDA Label Image

43063617 Label (43063617)

43063617 Label (43063617)
Label for Levetiracetam USP oral film-coated tablets, 500 mg strength, containing 60 tablets per bottle. The label includes the NDC 43063-617-60 and shows PD-Rx Pharmaceuticals, Inc. as the labeler based in Oklahoma City, OK. Additional information includes lot number SAMPLE and expiration date 01/50. The label also contains usage directions fields and a warning to keep the product out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.